drugset / Trial / NCT05748561

Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.

NCT05748561

Phase 2/3 Unknown 18 enrolled Asociación para Evitar la Ceguera en México
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4 weeks after therapeutic intervention. The main question it aims to answer: • Is there a difference in the visual recovery of toxic optic neuropathies treated with intravenous methylprednisolone in comparison with those treated with intravenous erythropoietin?

Timeline

Start
2022-04-05
Primary completion
2024-04-05
Completion
2024-04-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 1 g Intravenous
Subject epoetin alfa Protein / enzyme biologic 10000 iu Intravenous